Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5425-5430

  Ravandi, Farhad ^a   Aribi, Ahmed ^a   O'Brien, Susan ^a   Faderl, Stefan ^a   Jones, Dan ^a   Ferrajoli, Alessandra ^a   Huang, Xuelin ^a   York, Sergernne ^a   Pierce, Sherry ^a   Wierda, William ^a   Kontoyiannis, Dimitrios ^a   Verstovsek, Srdan ^a   Pro, Barbara ^a   Fayad, Luis ^a   Keating, Michael ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; PENTOSTATIN; T LYMPHOCYTE RECEPTOR; VALACICLOVIR; VALGANCICLOVIR; VORICONAZOLE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PNEUMONIA; BLOOD SAMPLING; BONE MARROW; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; EPIDIDYMITIS; FEMALE; GENE REARRANGEMENT; HERPES SIMPLEX VIRUS; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTION; PARAINFLUENZA VIRUS INFECTION; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEPSIS; SIDE EFFECT; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; VIRUS PNEUMONIA; VIRUS REACTIVATION; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PENTOSTATIN; SEPSIS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73949103860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.6688     Document Type: Article

References (30)

1. Ravandi F, Kantarjian H, Jones D, et al: Mature T-cell leukemias. Cancer 104:1808-1818, 2005
2. Catovsky D, Galetto J, Okos A, et al: Prolymphocytic leukaemia of B and T cell type. Lancet 2:232-234, 1973
3. Matutes E, Brito-Babapulle V, Swansbury J, et al: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78:3269-3274, 1991
4. Herling M, Khoury JD, Washington LT, et al: A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104:328-335, 2004
5. Dearden C, Matutes E, Catovsky D: Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 64:903-906, 1991
6. Dearden CE, Matutes E, Cazin B, et al: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98:1721-1726, 2001
7. Keating MJ, Cazin B, Coutre S, et al: Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20:205-213, 2002
8. Dearden CE, Foss FM: Peripheral T-cell lymphomas: Diagnosis and management. Hematol Oncol Clin North Am 17:1351-1366, 2003
9. Zinzani PL, Magagnoli M, Bendandi M, et al: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351-1353, 1998
10. Tsimberidou AM, Giles F, Duvic M, et al: Phase II study of pentostatin in advanced T-cell lymphoid malignancies: Update of an M. D. Anderson Cancer Center series. Cancer 100:342-349, 2004
11. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920-2924, 2004
12. Zinzani PL, Alinari L, Tani M, et al: Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90:702-703, 2005
13. Lundin J, Hagberg H, Repp R, et al: Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 101:4267-4272, 2003
14. Vega F, Medeiros LJ, Bueso-Ramos C, et al: Hepatosplenic gamma/delta T-cell lymphoma in bone marrow: A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 116:410-419, 2001
15. Belhadj K, Reyes F, Farcet JP, et al: Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 102:4261-4269, 2003
16. Siegel RS, Gartenhaus RB, Kuzel TM: Human T-cell lymphotropic-I- associated leukemia/lymphoma. Curr Treat Options Oncol 2:291-300, 2001
17. Pawson R, Richardson DS, Pagliuca A, et al: Adult T-cell leukemia/lymphoma in London: Clinical experience of 21 cases. Leuk Lymphoma 31:177-185, 1998
18. Taguchi H, Kinoshita KI, Takatsuki K, et al: An intensive chemotherapy of adult T-cell leukemia/ lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 12:182-186, 1996
19. Tsukasaki K, Tobinai K, Shimoyama M, et al: Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 77:164-170, 2003
20. Catovsky D, Ralfkiaer E, Muller-Hermelink HK: T-cell prolymphocytic leukaemia, in Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 195-196
21. O'Brien S, Ravandi F, Riehl T, et al: Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111:1816-1819, 2008
22. Vega F, Medeiros LJ, Jones D, et al: A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 116:17-24, 2001
23. Thall PF, Simon RM, Estey EH: New statistical strategy for monitoring safety and efficacy in singlearm clinical trials. J Clin Oncol 14:296-303, 1996
24. Ravandi F, Faderl S: Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 30:103-105, 2006
25. Dearden CE, Matutes E, Cazin B, et al: Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy. Blood 102:644a, 2003 (abstr)
26. Hopfinger G, Busch R, Eichhorst B, et al: T-PLL-1 protocol of the German CLL Study Group (GCLLSG): A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL. Blood 106:2130, 2005 (abstr)
27. Wierda W, Faderl S, O'Brien S, et al: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 104:340, 2004 (abstr)
28. Weiss MA, Maslak PG, Jurcic JG, et al: Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21:1278-1284, 2003
29. Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581, 2006
30. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007